Verrica announces positive results for molluscum contagiosum treatment
Category: #health  By Mateen Dalal  Date: 2019-03-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

Verrica announces positive results for molluscum contagiosum treatment

The treatment would help to address unmet medical needs against serious skin lesions

Reports suggest that the lead candidate of Verrica Pharmaceuticals, a drug-device combination for dermatology indication, has achieved primary endpoints in two of the Phase 3 trials while testing in molluscum contagiosum, a skin infection.

Apparently, this treatment beat out placebo in reducing the number of lesions and completely clearing treatable lesions in both studies. The Pennsylvania-based firm is planning to file a New Drug Application (NDA) for the asset, termed as VP-102, in second half of year 2019.

Lead investigator for the VP-102 phase 3 molluscum program and Chief of adolescent and pediatric dermatology at Rady Children’s Hospital-San Diego, Lawrence Eichenfield, M.D., mentioned that the current methods of treatment have huge limitations, which include unproven efficacy, scarring, pain. Also, many are not suitable for use in children, he stated.

Eichenfield further said that VP-102 addresses unmet medical needs for treating serious skin lesions that could spread very quickly among children and within families, if it is left untreated, could lead towards secondary infections, skin inflammation, anxiety and social stigma.

The data, which was presented at the American Academy of Dermatology’s annual meeting, has allegedly followed topline results announced in January. Both the trails, known as CAMP-1 and CAMP-2, had been randomized, placebo-controlled double-blind trials which pitted VP-102 against placebo in 528 patients suffering from molluscum. In a single-use applicator, VP-102 is a topical treatment which contains a solution of 0.7 percent cantharidin.

Further from the reports, for up to a total of 12 weeks, patients were treated once in every three weeks. Studies revealed that 26 percent of patients treated in CAMP-1 and 54 percent of patients treated in CAMP-2 had finished clearance of all treatable molluscum lesions.

Purportedly, the placebo group numbers were 18 percent and 13 percent, respectively. In mean reduction of the number of lesions, VP-102 performed similarly, 69 percent and 83 percent reduction in CAMP-1 and CAMP-2. Placebo patients in CAMP-2 had a 19 percent reduction, while those in CAMP-1 had a 20% increase.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...